Goodwin advised Rubius Therapeutics on its $120 million private financing round. The proceeds will be used to accelerate the advancement of Rubius’ breakthrough Red-Cell Therapeutics™ (RCT™) product portfolio, to further build out the team and to prepare to enter human clinical trials in 2018. The financing follows the successful achievement of key milestones for Rubius, including the clinical scale production of cultured red cells in bioreactors and the generation of preclinical proof-of-concept data for several lead programs.
Launched in 2014, Rubius Therapeutics is using breakthrough science to develop an entirely new class of drugs with the potential to treat many areas of human disease. The Rubius Erythrocyte Design (RED)™ platform enables Rubius scientists to genetically modify, culture and mature hematopoietic stem cells to create allogeneic, functionalized Red-Cell Therapeutics™.